Loading stock data…
AGIO
$28.77+0.35 (+1.23%)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agios Pharmaceuticals, Inc. in the Healthcare sector is trading at $28.77. Wall Street consensus targets $41.12 (8 analysts), implying a +42.9% move over the next 12 months. The stock is currently 37% below its 52-week high of $46.00, remaining 12.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$28.77
Potential Downside
0%
Whystock Fair Value$28.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$41.13+42.9%
Range$28.00 – $60.00
Fundamentals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.60%
Volume
Today's trading volume
692,744
Recent News
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation
Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA seeking accelerated approval of mitapivat for sickle cell disease. The filing is backed by positive Phase 3 trial results in sickle cell disease. These Phase 3 data are scheduled for a Plenary Abstracts Session at the upcoming EHA Congress. For investors watching Agios Pharmaceuticals (NasdaqGS:AGIO), this regulatory move comes with the stock trading at $28.42 and a mixed return profile, including a gain of...
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Sector Update: Healthcare Stocks Gain in Afternoon Trading
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State S
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.